Know Cancer

forgot password

A Randomized, Double-Blind, Phase III Study of Indinavir Sulfate With Open-Label Zidovudine (AZT) and Lamivudine (3TC) in Subjects With HIV Infection With CD4 Cell Counts <= 200 Cells/mm3 and >= 6 Months of Prior AZT Experience

Phase 3
18 Years
Not Enrolling
HIV Infections

Thank you

Trial Information

A Randomized, Double-Blind, Phase III Study of Indinavir Sulfate With Open-Label Zidovudine (AZT) and Lamivudine (3TC) in Subjects With HIV Infection With CD4 Cell Counts <= 200 Cells/mm3 and >= 6 Months of Prior AZT Experience

Protease inhibitors such as indinavir sulfate may be effective in patients with advanced HIV
disease who have received prior AZT therapy. Since studies suggest that triple drug therapy
may have an advantage over both monotherapy and two drug therapy, the combination of
indinavir sulfate with AZT and 3TC should be evaluated.

Patients are randomized to receive open-label AZT and 3TC with or without indinavir sulfate
for at least 48 weeks. Patients who develop intolerance to AZT or have progressive disease
after 24 weeks on study may substitute stavudine ( d4T ) for AZT. Patients are followed at
weeks 4, 8, 16, 24, 32, 40, and 48 and every 8 weeks thereafter up to week 96. [AS PER
02/25/97 AMENDMENT: Accrual has been halted because interim analysis has shown triple
therapy superior to double-agent therapy. An open label extension phase has been added for
the period through 06/30/97. Patients who had been randomized to AZT/3TC are given the
option of continuing on assigned ACTG 320 study drugs, crossing over to open-label
indinavir, or permanently discontinuing all study therapies and going off study. Patients
who were randomized to AZT/3TC plus indinavir or who were crossed to such therapy are given
the option of continuing their currently assigned therapies. It is strongly suggested that
patients who were on AZT/3TC who wish to receive open-label indinavir consider changing the
nucleoside analog component of their regimen if at all possible.] [ AS PER 06/06/97
AMENDMENT: The availability of the current ACTG 320 treatment has been further extended for
approximately 12 additional weeks (but not beyond 09/30/97). This extension will allow
patients to continue receiving study medications until ACTG 372 is open to accrual (the
rollover protocol for subjects originally randomized to the triple drug component of ACTG
320 or who are crossed over due to a confirmed study endpoint is finalized).] [ AS PER
09/15/97 AMENDMENT: Open-label therapy will be provided for no more than 90 days beyond the
enrollment of the first subject on ACTG 372.]

Inclusion Criteria

Inclusion Criteria

Concurrent Medication:


- PCP prophylaxis.


- Topical or oral antifungal agents (other than oral ketoconazole).

- Approved agents for opportunistic infections.

- Antibiotics unless specifically excluded.

- Systemic corticosteroids for no more than 21 days.

- Vitamins.

- Recombinant erythropoietin.

- G-CSF.

- Regularly prescribed medications such as allergy medications, antidepressants,
antipyretics, analgesics, oral contraceptives, megestrol, and testosterone.

Concurrent Treatment:


- Acupuncture.

- Visualization techniques.

Patients must have:

- HIV infection.

- CD4 count <= 200 cells/mm3.

- At least 6 months total prior AZT therapy.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

- Malignancy requiring systemic therapy other than minimal Kaposi's sarcoma.

Concurrent Medication:


- Antiretrovirals other than study drugs.

- Rifabutin and rifampin.

- Investigational drugs other than indinavir sulfate.

- Systemic cytotoxic chemotherapy.

- Oral ketoconazole.

- Chronic systemic corticosteroids.

- Herbal therapies.

Patients with the following prior conditions are excluded:

- Unexplained temperature > 38.5 C for any 7 days within 30 days prior to study entry.

- Chronic diarrhea persisting for 15 days within 30 days prior to study entry.

- History of acute or chronic pancreatitis.

- Acute hepatitis within 30 days prior to study entry.

- Grade 2 or worse bilateral peripheral neuropathy within 60 days prior to study entry.

- Dose-limiting intolerance to prior AZT at 600 mg/day.

Prior Medication:


- More than 1 week of prior 3TC.

- Any prior protease inhibitors.

- Rifampin or rifabutin within 14 days prior to study entry.

Excluded within 30 days prior to study entry:

- Erythropoietin.

- G-CSF or GM-CSF.

- Non-nucleoside reverse transcriptase inhibitors.

- Interferons.

- Interleukins.

- HIV vaccines.

- Any experimental therapy.

Type of Study:


Study Design:

Primary Purpose: Treatment

Principal Investigator

Hammer SM

Investigator Role:

Study Chair


United States: Federal Government

Study ID:

ACTG 320



Start Date:

Completion Date:

June 1997

Related Keywords:

  • HIV Infections
  • Drug Therapy, Combination
  • Acquired Immunodeficiency Syndrome
  • Antiviral Agents
  • Zidovudine
  • Stavudine
  • HIV Protease Inhibitors
  • Lamivudine
  • Indinavir
  • HIV Infections
  • Acquired Immunodeficiency Syndrome



San Francisco Gen Hosp San Francisco, California  941102859
Bellevue Hosp / New York Univ Med Ctr New York, New York  10016
Mem Sloan - Kettering Cancer Ctr New York, New York  10021
Univ of Rochester Medical Center Rochester, New York  14642
Julio Arroyo West Columbia, South Carolina  29169
UCLA CARE Ctr Los Angeles, California  90095
Univ of California / San Diego Treatment Ctr San Diego, California  921036325
San Francisco AIDS Clinic / San Francisco Gen Hosp San Francisco, California  941102859
Stanford at Kaiser / Kaiser Permanente Med Ctr San Francisco, California  94115
Harbor UCLA Med Ctr Torrance, California  90502
Univ of Colorado Health Sciences Ctr Denver, Colorado  80262
Univ of Miami School of Medicine Miami, Florida  331361013
Rush Presbyterian - Saint Luke's Med Ctr Chicago, Illinois  60612
Northwestern Univ Med School Chicago, Illinois  60611
Indiana Univ Hosp Indianapolis, Indiana  462025250
Tulane Univ School of Medicine New Orleans, Louisiana  70112
Harvard (Massachusetts Gen Hosp) Boston, Massachusetts  02114
Beth Israel Deaconess - West Campus Boston, Massachusetts  02215
Boston Med Ctr Boston, Massachusetts  02118
Univ of Minnesota Minneapolis, Minnesota  55455
Bronx Veterans Administration / Mount Sinai Hosp Bronx, New York  10468
SUNY / Erie County Med Ctr at Buffalo Buffalo, New York  14215
Cornell Univ Med Ctr New York, New York  10021
Mount Sinai Med Ctr New York, New York  10029
SUNY / State Univ of New York Syracuse, New York  13210
Univ of North Carolina Chapel Hill, North Carolina  275997215
Duke Univ Med Ctr Durham, North Carolina  27710
Ohio State Univ Hosp Clinic Columbus, Ohio  432101228
Milton S Hershey Med Ctr Hershey, Pennsylvania  170330850
Univ of Tennessee / E Tennessee Comprehensive Hemophilia Ctr Knoxville, Tennessee  37920
Univ of Washington Seattle, Washington  98105
Great Lakes Hemophilia Foundation Milwaukee, Wisconsin  53233
Johns Hopkins Hosp Baltimore, Maryland  21287
Charity Hosp / Tulane Univ Med School New Orleans, Louisiana  70112
St Louis Regional Hosp / St Louis Regional Med Ctr St Louis, Missouri  63112
Columbus Children's Hosp Columbus, Ohio  432052696
Univ of Alabama at Birmingham Birmingham, Alabama  35294
Univ of Southern California / LA County USC Med Ctr Los Angeles, California  900331079
Univ of Iowa Hosp and Clinic Iowa City, Iowa  52242
Hennepin County Med Clinic Minneapolis, Minnesota  55415
St Paul Ramsey Med Ctr St Paul, Minnesota  55101
Univ of Nebraska Med Ctr Omaha, Nebraska  681985130
Beth Israel Med Ctr New York, New York  10003
Saint Clare's Hosp and Health Ctr New York, New York  10019
Carolinas Med Ctr Charlotte, North Carolina  28203
Moses H Cone Memorial Hosp Greensboro, North Carolina  27401
Univ of Cincinnati Cincinnati, Ohio  452670405
Thomas Jefferson Univ Hosp Philadelphia, Pennsylvania  191075098
Children's Hosp of Los Angeles Los Angeles, California  90027
Stanford Univ Med Ctr Stanford, California  943055107
San Mateo AIDS Program / Stanford Univ Stanford, California  943055107
Mountain States Reg Hemo Ctr / Univ of Colorado Denver, Colorado  80262
Howard Univ Washington, District of Columbia  20059
George Washington Univ / Hershey Med Ctr Washington, District of Columbia  20037
Univ of Hawaii Honolulu, Hawaii  96816
Louis A Weiss Memorial Hosp Chicago, Illinois  60640
Methodist Hosp of Indiana / Life Care Clinic Indianapolis, Indiana  46202
Worcester Memorial Hosp / Med Ctr of Cntrl MA-Memorial Worcester, Massachusetts  01605
Montefiore Med Ctr Adolescent AIDS Program Bronx, New York  10467
North Shore Univ Hosp Manhasset, New York  11030
Mount Sinai Med Ctr / Hemophilia Treatment Ctr New York, New York  10029
Harlem Hosp Ctr New York, New York  10037
Univ of Kentucky Lexington Cincinnati, Ohio  45267
Case Western Reserve Univ Cleveland, Ohio  44106
Meharry Med College Nashville, Tennessee  37203
Univ of Texas Galveston Galveston, Texas  775550435
Univ Texas Health Science Ctr / Univ Texas Med School Houston, Texas  77030
Queens Med Ctr Honolulu, Hawaii  96816
Illinois Masonic Med Ctr Chicago, Illinois  606575147
Mount Sinai Med Ctr / Pediatrics New York, New York  10029
Kaiser Permanente Franklin Med Ctr Denver, Colorado  80262
Georgetown Univ Hosp Washington, District of Columbia  20037
Univ of Miami (Pediatric) Miami, Florida  33161
Emory Univ Atlanta, Georgia  30308
Emory Hemo Comp Evaluation Clinic / East TN Comp Hemo Ctr Atlanta, Georgia  303652225
Chicago Children's Memorial Hosp Chicago, Illinois  606143394
Division of Inf Diseases/ Indiana Univ Hosp Indianapolis, Indiana  46202
Tulane Med Ctr Hosp New Orleans, Louisiana  70112
State of MD Div of Corrections / Johns Hopkins Univ Hosp Baltimore, Maryland  212052196
Manhattan Veterans Administration / New York Univ Med Ctr New York, New York  10016
St Vincent's Hosp / Mem Sloan-Kettering Cancer Ctr New York, New York  10021
Kaplan Cancer Ctr / New York Univ Med Ctr New York, New York  10016
Central Prison/Women's Prison in Raleigh / NC Raleigh, North Carolina  276260540
Med Univ of South Carolina Charleston, South Carolina  294253312
Vanderbilt Univ Med Ctr Nashville, Tennessee  37203